Apriem Advisors’s Kite Pharma, Inc. KITE Stock Holding History

Apriem Advisors’s Portfolio KITE Stock Details KITE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-300	Closed	-$15K	–	671
2016 Q2	$15K	Buy	+300	New	+$14.7K	﹤0.01%	373
2015 Q3	–	Sell	-1,000	Closed	-$61K	–	648
2015 Q2	$61K	Buy	+1,000	New	+$57.1K	0.02%	192

Other funds holding KITE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Apriem Advisors's KITE Position: Q3 2016 in Review

Apriem Advisors sold out of Kite Pharma, Inc. (KITE) in Q3 2016, closing a stake of 300 shares — an estimated $15K sold.

Apriem Advisors first reported a position in KITE in Q2 2015 and held it in 2 quarters. The position peaked at $61K in Q2 2015. 195 funds tracked by Wall St. Rank hold KITE as of Q3 2016.

Apriem Advisors reported no remaining Kite Pharma, Inc. position as of Q3 2016 after selling out during the quarter.
Apriem Advisors sold 300 Kite Pharma, Inc. shares in Q3 2016, an estimated $15K.
Apriem Advisors first reported a position in Kite Pharma, Inc. in Q2 2015 and held it in 2 quarters.
Apriem Advisors's Kite Pharma, Inc. position peaked at $61K in Q2 2015.
195 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q3 2016.

Based on Apriem Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.